AMI Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-40,931
| Closed | -$2.99M | – | 87 |
|
|
2024
Q1 | $2.99M | Sell |
40,931
-1,688
| -4% | -$124K | 0.15% | 61 |
|
|
2023
Q4 | $3.04M | Buy |
42,619
+8,683
| +26% | +$512K | 0.17% | 57 |
|
|
2023
Q3 | $2.03M | Sell |
33,936
-11,360
| -25% | -$748K | 0.13% | 62 |
|
|
2023
Q2 | $3.27M | Buy |
45,296
+17,404
| +62% | +$1.31M | 0.19% | 53 |
|
|
2023
Q1 | $2.05M | Buy |
27,892
+7,015
| +34% | +$499K | 0.13% | 59 |
|
|
2022
Q4 | $1.4M | Sell |
20,877
-24,518
| -54% | -$1.59M | 0.1% | 65 |
|
|
2022
Q3 | $2.44M | Sell |
45,395
-21,657
| -32% | -$1.27M | 0.18% | 62 |
|
|
2022
Q2 | $3.73M | Sell |
67,052
-1,157
| -2% | -$65.7K | 0.24% | 64 |
|
|
2022
Q1 | $4.79M | Buy |
68,209
+3,347
| +5% | +$243K | 0.25% | 63 |
|
|
2021
Q4 | $6.25M | Sell |
64,862
-14,161
| -18% | -$1.31M | 0.3% | 56 |
|
|
2021
Q3 | $6.87M | Buy |
79,023
+2,685
| +4% | +$208K | 0.34% | 62 |
|
|
2021
Q2 | $6.25M | Buy |
76,338
+1,180
| +2% | +$98.2K | 0.31% | 61 |
|
|
2021
Q1 | $7.15M | Sell |
75,158
-19,138
| -20% | -$1.81M | 0.37% | 52 |
|
|
2020
Q4 | $5.85M | Sell |
94,296
-68,998
| -42% | -$3.93M | 0.29% | 59 |
|
|
2020
Q3 | $9.71M | Sell |
163,294
-3,173
| -2% | -$217K | 0.49% | 48 |
|
|
2020
Q2 | $11.6M | Buy |
166,467
+18,428
| +12% | +$1.17M | 0.62% | 37 |
|
|
2020
Q1 | $6.72M | Sell |
148,039
-1,989
| -1% | -$113K | 0.42% | 54 |
|
|
2019
Q4 | $9.76M | Sell |
150,028
-13,249
| -8% | -$885K | 0.48% | 48 |
|
|
2019
Q3 | $10.1M | Sell |
163,277
-31,473
| -16% | -$1.98M | 0.53% | 44 |
|
|
2019
Q2 | $13.9M | Buy |
194,750
+32,834
| +20% | +$2.42M | 0.69% | 48 |
|
|
2019
Q1 | $12.7M | Buy |
161,916
+29,733
| +22% | +$2.25M | 0.94% | 38 |
|
|
2018
Q4 | $11.2M | Buy |
132,183
+31,771
| +32% | +$3.39M | 0.92% | 37 |
|
|
2018
Q3 | $17.2M | Sell |
100,412
-41,761
| -29% | -$6.3M | 1.17% | 33 |
|
|
2018
Q2 | $18.4M | Sell |
142,173
-28,801
| -17% | -$3.21M | 1.31% | 31 |
|
|
2018
Q1 | $17.6M | Sell |
170,974
-24,534
| -13% | -$2.43M | 1.26% | 30 |
|
|
2017
Q4 | $16.7M | Sell |
195,508
-30,127
| -13% | -$2.61M | 1.15% | 32 |
|
|
2017
Q3 | $19.2M | Buy |
225,635
+4,370
| +2% | +$346K | 1.36% | 29 |
|
|
2017
Q2 | $16.8M | Buy |
221,265
+37,184
| +20% | +$2.6M | 1.2% | 32 |
|
|
2017
Q1 | $12.2M | Sell |
184,081
-47,791
| -21% | -$3.14M | 0.92% | 38 |
|
|
2016
Q4 | $14.7M | Sell |
231,872
-11,034
| -5% | -$696K | 1.09% | 45 |
|
|
2016
Q3 | $15.5M | Buy |
242,906
+22,543
| +10% | +$1.66M | 1.07% | 41 |
|
|
2016
Q2 | $16.4M | Sell |
220,363
-66,532
| -23% | -$4.94M | 1.14% | 39 |
|
|
2016
Q1 | $19.2M | Buy |
286,895
+30,306
| +12% | +$1.84M | 1.32% | 30 |
|
|
2015
Q4 | $17.4M | Buy |
256,589
+17,696
| +7% | +$1.09M | 1.21% | 33 |
|
|
2015
Q3 | $12.8M | Buy |
238,893
+85,989
| +56% | +$5.22M | 0.98% | 38 |
|
|
2015
Q2 | $9.62M | Buy |
+152,904
| New | +$8.34M | 0.72% | 51 |
|
Other funds holding LGND
SIMG
CAM
CC
SDJVC
AMI Asset Management's LGND Position: Q2 2024 in Review
AMI Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 40,931 shares — an estimated $2.99M sold.
AMI Asset Management first reported a position in LGND in Q2 2015 and held it in 36 quarters. The position peaked at $19.2M in Q1 2016. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.
- AMI Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- AMI Asset Management sold 40,931 Ligand Pharmaceuticals shares in Q2 2024, an estimated $2.99M.
- AMI Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 36 quarters.
- AMI Asset Management's Ligand Pharmaceuticals position peaked at $19.2M in Q1 2016.
- 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.
Based on AMI Asset Management's 13F filing for Q2 2024, filed 25 Jul 2024.